Moderna stock holds steady amid regulatory review of mRNA-1010 in US, EU, Canada, Australia

Traders Union
All News
Financial News
Moderna slides 0.40% despite trial win

Highlights

Moderna's mRNA-1010 seasonal flu vaccine delivered superior efficacy to a standard-dose competitor in a large Phase 3 trial.
Ongoing regulatory submissions across the US, Europe, Canada, and Australia position Moderna for expanded market opportunities and potential new revenue streams.
Shares trade under short- and medium-term pressure, but longer-term momentum remains intact; price expected in the $46.00–$51.50 corridor near-term.

Regulatory momentum and strong trial data outweigh weak price action

On May 6, 2026, Moderna reported the publication of positive Phase 3 clinical trial results for its mRNA-1010 seasonal influenza vaccine candidate in the New England Journal of Medicine. The data showed superior efficacy against a licensed standard-dose vaccine, including detailed relative efficacy outcomes for multiple influenza strains and in participants over 65. Regulatory submissions for mRNA-1010 are ongoing in the United States, Europe, Canada, and Australia, which broadens Moderna's prospects for market entry and future revenue, though price action has remained under broader selling pressure.

Mixed momentum as resistance challenges price and signals diverge

Technically, MRNA is trading below the SMA-20 at $50.60 and SMA-50 at $51.60, while holding well above the SMA-200 at $35.94. The Ichimoku Kijun level at $49.95 presents immediate resistance near the current price. Momentum indicators on the daily chart are mixed: MACD and ADX are both showing a sell bias with weakening upside, while RSI, CCI, and Stoch RSI point to a lack of clear directional conviction. The Bull/Bear Power (BBP) is at an oversold reading of 0.32, skewing intraday sentiment toward sellers, and the Awesome Oscillator does not confirm a strong trend, suggesting notable divergence among momentum signals.

Sideways movement likely as volatility persists and signals diverge

In the near term, typical volatility for MRNA is projected to keep the price within a $46.00 to $51.50 band over the next five sessions. With three out of four weekly trend indicators still showing a Buy signal, the probability of upward movement is moderate at approximately 75%, while the likelihood of a decline is lower. The baseline forecast anticipates MRNA trading sideways within this volatility band, constrained by overlapping technical signals and support from long-term moving averages. Upside acceleration could occur on a breakout above resistance near $50.00 to $51.50, whereas a drop through support at $46.00 would open the door to further short-term downside, though a sharp breakdown is viewed as unlikely for now.

Anton Kharitonov, expert at Traders Union, notes that Moderna’s strong clinical results and pending regulatory reviews provide a constructive foundation, but price action remains soft. He sees technical indicators as mixed, with resistance overhead and only modest support from long-term averages. The near-term setup is neutral, as volatility could persist between $46.00 and $51.50 absent a breakout. "Until we see a clear move above $51.50 or a decisive breakdown below $46.00, the stock is likely to remain rangebound and directionless."

Earlier, analysts noted that despite Moderna facing ongoing legal and regulatory uncertainties, the long-term trend remained supportive even as short-term pressures persisted. The latest positive Phase 3 data for mRNA-1010 and ongoing global regulatory submissions add a constructive catalyst to the outlook, positioning the stock for a potential shift in sentiment if resistance near $51.50 is broken in the coming sessions.

Source of Data: MRNA Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.